ANL 27.70 Increased By ▲ 0.20 (0.73%)
ASC 17.02 Increased By ▲ 0.01 (0.06%)
ASL 24.08 Increased By ▲ 0.18 (0.75%)
AVN 96.11 Increased By ▲ 2.42 (2.58%)
BOP 9.52 Increased By ▲ 0.01 (0.11%)
BYCO 9.78 Increased By ▲ 0.03 (0.31%)
DGKC 112.20 Increased By ▲ 1.95 (1.77%)
EPCL 48.30 Increased By ▲ 0.51 (1.07%)
FCCL 21.50 Increased By ▲ 0.23 (1.08%)
FFBL 27.53 Increased By ▲ 0.12 (0.44%)
FFL 19.00 Increased By ▲ 0.20 (1.06%)
HASCOL 14.52 Decreased By ▼ -0.04 (-0.27%)
HUBC 86.20 Decreased By ▼ -0.47 (-0.54%)
HUMNL 7.56 Increased By ▲ 0.23 (3.14%)
JSCL 31.91 Increased By ▲ 0.97 (3.14%)
KAPCO 41.50 Increased By ▲ 0.45 (1.1%)
KEL 4.17 Increased By ▲ 0.07 (1.71%)
LOTCHEM 16.67 Increased By ▲ 0.42 (2.58%)
MLCF 43.69 Increased By ▲ 0.67 (1.56%)
PAEL 39.83 Decreased By ▼ -0.07 (-0.18%)
PIBTL 13.05 Increased By ▲ 0.44 (3.49%)
POWER 11.79 Increased By ▲ 0.40 (3.51%)
PPL 94.00 No Change ▼ 0.00 (0%)
PRL 24.25 Increased By ▲ 0.26 (1.08%)
PTC 9.47 Decreased By ▼ -0.03 (-0.32%)
SILK 1.28 Increased By ▲ 0.02 (1.59%)
SNGP 45.20 Increased By ▲ 0.20 (0.44%)
TRG 107.28 Increased By ▲ 0.83 (0.78%)
UNITY 33.95 Decreased By ▼ -0.23 (-0.67%)
WTL 1.13 No Change ▼ 0.00 (0%)
BR100 4,868 Increased By ▲ 34.57 (0.72%)
BR30 24,884 Increased By ▲ 190.31 (0.77%)
KSE100 45,949 Increased By ▲ 271.79 (0.6%)
KSE30 19,133 Increased By ▲ 107.76 (0.57%)
World

Germany approves third trial of COVID-19 vaccine candidate

  • Hundreds of potential COVID-19 vaccines are in various stages of development, with 41 prospects in human trials across the globe.
02 Oct 2020

BERLIN: Unlisted biotech firm IDT Biologika has won approval from Germany's vaccine regulator to become the third German company after BioNTech and CureVac to launch human trials of an experimental coronavirus vaccine in the country.

The trial of the vaccine, which has been developed with the German Centre for Infection Research (DZIF), will be conducted on 30 participants aged between 18 and 55 who will receive two vaccinations at four-week intervals.

A larger Phase II trial, which will include elderly volunteers, is planned for the end of this year if the results of the early-stage study show the vaccine is safe and produces an immune response.

Based in Dessau-Rosslau in east Germany, IDT produces viral vaccines for pharmaceutical companies and is assisting in six COVID-19 projects including AstraZeneca's experimental shot against COVID-19.

Its own so-called viral vector vaccine is based on a modified and harmless smallpox virus that has already been used to develop a vaccine against the coronavirus that causes the Middle East Respiratory Syndrome (MERS).

Hundreds of potential COVID-19 vaccines are in various stages of development, with 41 prospects in human trials across the globe.

Russia and China have already deployed shots before full efficacy trials have been concluded, and front-runners from Pfizer, Moderna and AstraZeneca are likely to have final-stage trial results before year-end.

Germany has awarded vaccine makers BioNTech and CureVac 627 million euros ($734.78 million) to help speed up work on their COVID-19 shots and expand German production capacity.

It is also in talks with IDT about providing funding.